FACS analyses of hematopoietic tissues from EPAS1 null or wild-type littermate donor (CD45.2)/B6-Ptprc recipient (CD45.1) mice
Tissue and epitope . | WT ± SEM . | KO ± SEM . |
|---|---|---|
| Bone marrow | ||
| CD45.2, % total cells | 92.3 ± 0.8 | 93.3 ± 0.2 |
| CD45.1, % total cells | 2.2 ± 0.5 | 0.8 ± 0.1 |
| CD3, % CD45.2 | 2.8 ± 0.3 | 2.5 ± 0.3 |
| B220, % CD45.2 | 28.3 ± 1.8 | 29.0 ± 1.0 |
| MAC-1, % CD45.2 | 69.5 ± 2.5 | 67.7 ± 3.0 |
| GR-1, % CD45.2 | 58.0 ± 1.7 | 55.6 ± 2.3 |
| TER-119, % CD45.2 | 3.4 ± 0.5 | 4.6 ± 0.9 |
| C-KIT, % CD45.2 | 3.4 ± 0.6 | 2.7 ± 0.3 |
| SCA-1, % CD45.2 | 6.4 ± 0.8 | 7.0 ± 0.7 |
| Spleen | ||
| CD45.2, % total cells | 86.1 ± 1.2 | 88.1 ± 2.2 |
| CD45.1, % total cells | 7.1 ± 0.9 | 6.9 ± 1.2 |
| CD3, % CD45.2 | 42.5 ± 1.3 | 45.4 ± 3.1 |
| B220, % CD45.2 | 51.9 ± 2.5 | 50.9 ± 3.4 |
| NK 1.1, % CD45.2 | 3.1 ± 0.7 | 4.2 ± 0.5 |
| Thymus | ||
| CD45.2, % total cells | 98.3 ± 0.5 | 97.4 ± 0.9 |
| CD45.1, % total cells | 0.3 ± 0.1 | 0.3 ± 0.1 |
| CD8, % CD45.2 | 87.0 ± 1.5 | 89.0 ± 1.1 |
| CD4, % CD45.2 | 94.1 ± 1.8 | 95.0 ± 0.6 |
| Lymph node | ||
| CD45.2, % total cells | 86.0 ± 0.8 | 89.0 ± 1.4 |
| CD45.1, % total cells | 13.5 ± 0.8 | 10.4 ± 1.5 |
| B220, % CD45.2 | 14.5 ± 1.5 | 16.9 ± 5.7 |
| CD8, % CD45.2 | 30.5 ± 2.4 | 28.8 ± 2.3 |
| CD4, % CD45.2 | 56.6 ± 2.7 | 52.9 ± 2.9 |
| Peripheral blood | ||
| CD45.2, % total cells | 91.2 ± 2.1 | 91.5 ± 1.2 |
| CD45.1, % total cells | 7.9 ± 2.06 | 7.6 ± 1.2 |
| MAC-1, % CD45.2 | 7.1 ± 1.4 | 5.5 ± 1.7 |
Tissue and epitope . | WT ± SEM . | KO ± SEM . |
|---|---|---|
| Bone marrow | ||
| CD45.2, % total cells | 92.3 ± 0.8 | 93.3 ± 0.2 |
| CD45.1, % total cells | 2.2 ± 0.5 | 0.8 ± 0.1 |
| CD3, % CD45.2 | 2.8 ± 0.3 | 2.5 ± 0.3 |
| B220, % CD45.2 | 28.3 ± 1.8 | 29.0 ± 1.0 |
| MAC-1, % CD45.2 | 69.5 ± 2.5 | 67.7 ± 3.0 |
| GR-1, % CD45.2 | 58.0 ± 1.7 | 55.6 ± 2.3 |
| TER-119, % CD45.2 | 3.4 ± 0.5 | 4.6 ± 0.9 |
| C-KIT, % CD45.2 | 3.4 ± 0.6 | 2.7 ± 0.3 |
| SCA-1, % CD45.2 | 6.4 ± 0.8 | 7.0 ± 0.7 |
| Spleen | ||
| CD45.2, % total cells | 86.1 ± 1.2 | 88.1 ± 2.2 |
| CD45.1, % total cells | 7.1 ± 0.9 | 6.9 ± 1.2 |
| CD3, % CD45.2 | 42.5 ± 1.3 | 45.4 ± 3.1 |
| B220, % CD45.2 | 51.9 ± 2.5 | 50.9 ± 3.4 |
| NK 1.1, % CD45.2 | 3.1 ± 0.7 | 4.2 ± 0.5 |
| Thymus | ||
| CD45.2, % total cells | 98.3 ± 0.5 | 97.4 ± 0.9 |
| CD45.1, % total cells | 0.3 ± 0.1 | 0.3 ± 0.1 |
| CD8, % CD45.2 | 87.0 ± 1.5 | 89.0 ± 1.1 |
| CD4, % CD45.2 | 94.1 ± 1.8 | 95.0 ± 0.6 |
| Lymph node | ||
| CD45.2, % total cells | 86.0 ± 0.8 | 89.0 ± 1.4 |
| CD45.1, % total cells | 13.5 ± 0.8 | 10.4 ± 1.5 |
| B220, % CD45.2 | 14.5 ± 1.5 | 16.9 ± 5.7 |
| CD8, % CD45.2 | 30.5 ± 2.4 | 28.8 ± 2.3 |
| CD4, % CD45.2 | 56.6 ± 2.7 | 52.9 ± 2.9 |
| Peripheral blood | ||
| CD45.2, % total cells | 91.2 ± 2.1 | 91.5 ± 1.2 |
| CD45.1, % total cells | 7.9 ± 2.06 | 7.6 ± 1.2 |
| MAC-1, % CD45.2 | 7.1 ± 1.4 | 5.5 ± 1.7 |
FACS profiles of bone marrow, splenic, thymic, or lymph node hematopoietic cells from irradiated B6-Ptprca recipient (CD45.1+) mice reconstituted with EPAS1/HIF-2α null or wild-type littermate donor (CD45.2+) BM HSCs. WT indicates wild-type; KO, knockout.